Zenlabs Ethica Limited (BOM:530697)

Market Cap	164.05M
Revenue (ttm)	496.19M
Net Income (ttm)	2.47M
Shares Out	6.51M
EPS (ttm)	0.38
PE Ratio	65.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,518
Average Volume	5,941
Open	26.20
Previous Close	24.83
Day's Range	24.95 - 26.99
52-Week Range	24.51 - 44.29
Beta	-0.96
RSI	34.03
Earnings Date	Nov 8, 2025

About Zenlabs Ethica

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530697

Financial Performance

In 2024, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.